The state of Texas is currently investigating two medical insurance companies, Blue Cross Blue Shield of Texas and UnitedHealth Group, over allegations of delays and denials of urgent medically necessary care. This investigation was sparked by concerns over the control that insurance companies have over access to medical care and who is accountable for the consequences of their decisions.
The author of the article shares a personal experience of being diagnosed with thyroid cancer at the age of 20 and having to push for surgery despite being told it was slow-growing and could be delayed. The author's experience highlights the risks of delayed treatment and the importance of holding insurance companies accountable for their decisions.
The investigations into Blue Cross Blue Shield of Texas and UnitedHealth Group raise questions about the mechanisms that insurance companies use to control access to care, such as prior authorization, step therapy, and medical reviews. These mechanisms are intended to prevent waste, but they can become barriers to necessary treatment when insurance companies' financial interests conflict with medical evidence and patients' needs.
The article cites testimony from a nurse practitioner, Shelagh Larson, who described a case where a breast cancer patient was forced to try multiple treatments before being approved for an FDA-approved nonhormonal treatment. This example illustrates the problems that can arise when insurance companies' financial interests override medical evidence and patients' needs.